Apidel announces the signature of an agreement to collaborate with DNDi on the preclinical development of a topical treatment for Cutaneous Leishmaniasis, a neglected disease affecting between 0.7 to 1.2 million people worldwide. A promising drug candidate will be tested with Apidel’s proprietary drug delivery technology ApidSOL™.

Geneva, May 29 2017


Apidel announces the signature of an agreement to collaborate with DNDi on the preclinical development of a topical treatment for Cutaneous Leishmaniasis, a neglected disease affecting between 0.7 to 1.2 million people worldwide. A promising drug candidate will be tested with Apidel’s proprietary drug delivery technology ApidSOL™.
Apidel is a Geneva based early-stage pharmaceutical company providing proprietary drug delivery solutions for development of safer and more efficient therapeutic products. ApidSOL™ enables superior skin penetration of poorly soluble drugs.
Currently, there is no efficient topical treatment available for cutaneous leishmaniasis. A safe, affordable topical treatment, which could be stored in harsh conditions and self-administered represents an urgent, unmet need.
DNDi (Drugs for Neglected Diseases initiative) is a patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases – notably leishmaniasis, sleeping sickness, Chagas disease, filarial diseases, mycetoma, paediatric HIV, and hepatitis C – with several new drug candidates in its R&D pipeline.
Cutaneous leishmaniasis is a poverty-associated disease occurring mostly in subtropical regions or in displaced populations. It is a skin infection prompted by a parasite, resulting in multiple ulcers on exposed body parts causing serious disability and leaving deep scars which may induce serious social prejudice.

 

For further information :
DNDi https://www.dndi.org/
Apidel SA www.apidel.com
Vitalia Mitrovic, Apidel SA, Geneva

Find an actor

CES 2019 Las Vegas - Swiss Pavilion08.01.2019

Join the Swiss Pavilion during the Consumer Electronic Show from 8 to 11 January 2019 in Las Vegas, USA.

Industrialisé avec le soutien technologique du CSEM, SUN bioscience lance sa plateforme Gri3DTM.

cet outil représente une première et propulse les organoïdes dans une nouvelle La culture in vitro standardisée,...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn